Imugene and City of Hope doses first subject in Phase I solid tumour trial

Retrieved on: 2022-05-18 20:52:06

Tags for this article:

Click the tags to see associated articles and topics

Imugene and City of Hope doses first subject in Phase I solid tumour trial. View article details on hiswai:

Excerpt

An engineered antibody, pembrolizumab boosts the ability of the immune system to attack cancer-causing cells. Activation of the study site and ...

Article found on: www.clinicaltrialsarena.com